A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

By M. Kershaw, J. A. Westwood, L. Parker, Gang Wang, Z. Eshhar, S. Mavroukakis, D. White, J. Wunderlich, S. Canevari, Linda J. Rogers-Freezer and 4 more. Clinical Cancer Research, 2006

1,238 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/220272aef3989d11f747d8cb1038031acefd4746

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. S. Rosenberg
2. C. June
3. S. Grupp
4. Wendell A. Lim
5. D. Porter
6. N. Restifo
7. B. Levine
8. M. Dudley

In Immunology

1. S. Rosenberg
2. N. Restifo
3. M. Dudley
4. C. June
5. Jie Yang
6. R. Sherry
7. U. Kammula
8. M. Hughes

In Oncology

1. S. Rosenberg
2. C. June
3. Wendell A. Lim
4. N. Restifo
5. M. Dudley
6. J. Kochenderfer
7. S. Grupp
8. Jie Yang

Citations in the corpus

• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011, background): “However, in the initial human trials, T lymphocytes expressing first-generation CARs showed limited expansion and relatively short persistence (3, 9, 10).”
• Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (2016, background): “First-generation CARs consisting of the cytoplasmic domain of the Fc receptor g chain or the CD3z signaling modules alone, often become anergic, and do not elicit potent T cell antitumor effects (Brocker, 2000; Kershaw et al., 2006; Lamers et al., 2006).”
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011, background): “However, no clinical responses were seen in three patients with renal cancer who received autologous T cells transduced with a CAR directed against carbonic anhydrase-IX(18) or in eight patients with ovarian cancer who received autologous PBMCs transduced with a CAR directed against the -folate rece”
• The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “CAR T cells targeting folate receptor 1 alpha and CD171 in advanced ovarian cancer and neuroblastoma did not have toxicity or efficacy; however, the short persistence of the infused CAR T cells precludes interpretations on the safety of these targets (Kershaw et al., 2006).”